Metastatic Breast Cancer Video Perspectives

Nancy U. Lin, MD

Lin reports receiving research support from AstraZeneca, Genentech, Merck, Pfizer, Seagen and Zion Pharmaceuticals; honoraria from Affinia Therapeutics, Aleta BioPharma, Daiichi Sankyo, Denali Therapeutics, Olema Pharmaceuticals, Pfizer, Prelude Therapeutics, Puma, Seagens and Voyager Therapeutics; and royalties from Up-to-Date.
July 03, 2023
1 min watch
Save

VIDEO: Lesser-known challenges in metastatic breast cancer

Transcript

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So, I mean, one of the areas that I study is the issue of brain metastases in breast cancer, which, you know, is something that can be difficult to talk about, 'cause it's very emotionally charged. And you know, people don't like to talk about the idea that cancer could go to the brain, but it unfortunately can. And in certain types of breast cancer, like HER2+ or triple negative, it's actually quite common. And it's, you know, an area where we're still working on trying to improve access for patients with brain metastases to clinical trials. It's an area where it's really important to have multidisciplinary care. And we've been really good about doing that in early stage disease where people routinely will see a breast surgeon and a breast radiation oncologist and a medical oncologist. And everything's all very well oiled. But for patients who have brain metastases, it's a different type of radiation oncologist and a different type of surgeon, and potentially a neuro oncologist. And those connections can be harder to find, especially outside of, you know, large medical centers. And I think, you know, is a challenge both clinically as well as from a trial perspective for patients and providers.